- Home
- KEP vs BMRN Comparison
KEP vs BMRN Comparison
Compare KEP & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEP
- BMRN
- Stock Information
- Founded
- KEP 1961
- BMRN 1996
- Country
- KEP South Korea
- BMRN United States
- Employees
- KEP N/A
- BMRN N/A
- Industry
- KEP Electric Utilities: Central
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- KEP Utilities
- BMRN Health Care
- Exchange
- KEP Nasdaq
- BMRN Nasdaq
- Market Cap
- KEP 13.3B
- BMRN 12.1B
- IPO Year
- KEP N/A
- BMRN 1999
- Fundamental
- Price
- KEP $13.19
- BMRN $56.35
- Analyst Decision
- KEP
- BMRN Buy
- Analyst Count
- KEP 0
- BMRN 22
- Target Price
- KEP N/A
- BMRN $93.43
- AVG Volume (30 Days)
- KEP 861.9K
- BMRN 2.2M
- Earning Date
- KEP 07-11-2025
- BMRN 08-04-2025
- Dividend Yield
- KEP 0.35%
- BMRN N/A
- EPS Growth
- KEP 667.18
- BMRN 152.82
- EPS
- KEP 5.56
- BMRN 2.71
- Revenue
- KEP $64,053,841,898.00
- BMRN $2,950,227,000.00
- Revenue This Year
- KEP $5.65
- BMRN $12.23
- Revenue Next Year
- KEP $2.21
- BMRN $9.99
- P/E Ratio
- KEP $5.04
- BMRN $20.77
- Revenue Growth
- KEP 4.91
- BMRN 19.36
- 52 Week Low
- KEP $6.68
- BMRN $52.93
- 52 Week High
- KEP $14.79
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- KEP 61.96
- BMRN 49.58
- Support Level
- KEP $13.93
- BMRN $53.76
- Resistance Level
- KEP $14.79
- BMRN $56.25
- Average True Range (ATR)
- KEP 0.29
- BMRN 1.25
- MACD
- KEP 0.23
- BMRN 0.26
- Stochastic Oscillator
- KEP 65.92
- BMRN 66.79
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.